Research & development increased 18.7%
Research & development changed +18.7% from the comparable as-filed period.
$168.8M→$200.4M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →MDB financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Net income changed across a sign change
Net income changed +111.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
-$37.6M→$4.4M2 prior comparisons
Capital expenditure increased 43.9%
Capital expenditure changed +43.9% from the comparable as-filed period. The change ranks at the 33th percentile of 6 prior comparable changes.
$1.6M→$2.3M6 prior comparisons
Capex / revenue moved 4 bp higher
Capex / revenue changed +4 basis points from the comparable as-filed period.
0.29%→0.34%2 prior comparisons
Stock-based compensation increased 4.1%
Stock-based compensation changed +4.1% from the comparable as-filed period.
$132.4M→$137.8M3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.